US3709898A
(en)
|
1971-02-09 |
1973-01-09 |
Upjohn Co |
Process for the production of triazolobenzodiazepines and intermediates
|
US3681343A
(en)
|
1971-05-11 |
1972-08-01 |
Upjohn Co |
6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
|
US3812259A
(en)
|
1971-08-09 |
1974-05-21 |
Upjohn Co |
Animal feed and process
|
CH622019A5
(en)
|
1975-10-23 |
1981-03-13 |
Upjohn Co |
Process for the preparation of aminotriazolobenzodiazepines
|
FR2329668A1
(fr)
|
1975-10-27 |
1977-05-27 |
Upjohn Co |
Procede de preparation d'aminotriazolobenzodiazepines
|
EP0087850A1
(fr)
|
1982-01-04 |
1983-09-07 |
The Upjohn Company |
Benzodiazépines pour utiliser comme antihypertensifs
|
DE3435973A1
(de)
|
1984-10-01 |
1986-04-10 |
Boehringer Ingelheim KG, 6507 Ingelheim |
Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
|
ES2037013T3
(es)
|
1986-01-21 |
1993-06-16 |
Boehringer Ingelheim Kg |
Procedimiento para preparar tieno-1,4-diazepinas.
|
DE3724164A1
(de)
|
1986-07-25 |
1988-01-28 |
Boehringer Ingelheim Kg |
Neue 1,4-benzodiazepine, ihre herstellung und verwendung
|
ATE86256T1
(de)
|
1987-05-28 |
1993-03-15 |
Yoshitomi Pharmaceutical |
Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
|
JPH0676326B2
(ja)
|
1988-05-24 |
1994-09-28 |
吉富製薬株式会社 |
循環器系疾患治療薬
|
EP0368175A1
(fr)
|
1988-11-06 |
1990-05-16 |
Boehringer Ingelheim Kg |
3S,7S-3-(Morpholinocarbonyle)-5-(2-chlorophényle)-7,10-diméthyle-3,4-dihydro-2H,7H-cyclopenta[4,5]thiéno[3,4-f][1,2,4]triazolo[4,3-a][1,4]diazépine.
|
EP0387613A1
(fr)
|
1989-03-03 |
1990-09-19 |
Boehringer Ingelheim Kg |
Thiénodiazépines
|
YU133090A
(sh)
|
1989-07-12 |
1993-10-20 |
Boehringer Ingelheim Kg. |
Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
|
DE4010528A1
(de)
|
1990-04-02 |
1991-10-17 |
Boehringer Ingelheim Kg |
Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
|
DE4107521A1
(de)
|
1991-03-08 |
1992-09-10 |
Boehringer Ingelheim Kg |
Neue acylaminosubstituierte hetrazepine
|
JP3239364B2
(ja)
|
1991-10-11 |
2001-12-17 |
ウェルファイド株式会社 |
骨粗鬆症治療薬およびジアゼピン化合物
|
EP0661284A1
(fr)
|
1992-09-18 |
1995-07-05 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compose de thienodiazepine et son utilisation medicinale
|
CA2159344A1
(fr)
|
1993-03-30 |
1994-10-13 |
Minoru Moriwaki |
Agent inhibant l'adherence des cellules et thienotriazolodiazepine
|
JP3001979U
(ja)
|
1994-03-14 |
1994-09-06 |
有限会社マルセ木工 |
竿掛け具
|
WO1995032963A1
(fr)
|
1994-06-01 |
1995-12-07 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compose de thienylazole et compose de thienotriazolodiazepine
|
CN1168140A
(zh)
|
1995-01-06 |
1997-12-17 |
弗·哈夫曼-拉罗切有限公司 |
羟甲基咪唑并二氮杂䓬及其酯
|
ATE230600T1
(de)
|
1995-09-09 |
2003-01-15 |
Hoffmann La Roche |
Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
|
US5893397A
(en)
|
1996-01-12 |
1999-04-13 |
Bioject Inc. |
Medication vial/syringe liquid-transfer apparatus
|
CN1227555A
(zh)
|
1996-06-12 |
1999-09-01 |
日本烟草产业株式会社 |
细胞因子生成抑制剂、三氮䓬化合物及其中间体
|
US5693641A
(en)
|
1996-08-16 |
1997-12-02 |
Berlex Laboratories Inc. |
Bicyclic pyrimidine derivatives and their use as anti-coagulants
|
CN1109037C
(zh)
|
1996-09-13 |
2003-05-21 |
三菱制药株式会社 |
噻吩并-***并二氮杂䓬化合物及其医药用途
|
US6444664B1
(en)
|
1997-04-18 |
2002-09-03 |
Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) |
Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
|
US5993412A
(en)
|
1997-05-19 |
1999-11-30 |
Bioject, Inc. |
Injection apparatus
|
JPH11228576A
(ja)
|
1997-12-10 |
1999-08-24 |
Japan Tobacco Inc |
アポトーシス抑制剤
|
FR2779652B1
(fr)
|
1998-06-15 |
2001-06-08 |
Sod Conseils Rech Applic |
Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
|
US6413981B1
(en)
|
1999-08-12 |
2002-07-02 |
Ortho-Mcneil Pharamceutical, Inc. |
Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
|
US7589167B2
(en)
|
2000-02-22 |
2009-09-15 |
J. David Gladstone Institutes |
ZA loops of bromodomains
|
WO2001095912A1
(fr)
|
2000-06-16 |
2001-12-20 |
Mitsubishi Pharma Corporation |
Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
|
AU2001270297A1
(en)
|
2000-06-30 |
2002-01-14 |
Neurogen Corporation |
2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
|
US20060142257A1
(en)
|
2001-01-19 |
2006-06-29 |
Eberhard Nieschlag |
Male contraceptive formulation comprising norethisterone
|
US6979682B2
(en)
|
2001-02-23 |
2005-12-27 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
|
AU2002354846B2
(en)
|
2001-07-20 |
2007-08-02 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
|
KR100955589B1
(ko)
|
2001-09-04 |
2010-04-30 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
신규한 디하이드로프테리디논, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
US6806272B2
(en)
|
2001-09-04 |
2004-10-19 |
Boehringer Ingelheim Pharma Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
US20030216758A1
(en)
|
2001-12-28 |
2003-11-20 |
Angiotech Pharmaceuticals, Inc. |
Coated surgical patches
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
JP3096299U
(ja)
|
2003-02-20 |
2003-09-12 |
宇輪工業股▲ふん▼有限公司 |
足踏み式健康器
|
NZ542498A
(en)
|
2003-02-26 |
2009-01-31 |
Boehringer Ingelheim Pharma |
Dihydropteridinones, method for the production and use thereof in the form of drugs
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
WO2005002526A2
(fr)
|
2003-07-01 |
2005-01-13 |
President And Fellows Of Harvard College |
Procedes et compositions pour le traitement d'infections virales
|
AU2004272288B2
(en)
|
2003-09-18 |
2008-11-13 |
Novartis Ag |
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
|
EP1528056A1
(fr)
|
2003-10-29 |
2005-05-04 |
Academisch Ziekenhuis bij de Universiteit van Amsterdam |
Dérives de desoxynojirimycine et leurs utilisations en tant qu'inhibiteurs de glucosylceramidase
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
EP1784406A1
(fr)
|
2004-08-27 |
2007-05-16 |
Boehringer Ingelheim International GmbH |
Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments
|
GB0419161D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
TWI447120B
(zh)
|
2005-05-30 |
2014-08-01 |
Mitsubishi Tanabe Pharma Corp |
噻吩并***并苯二氮呯化合物、其醫藥上之用途
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
WO2007014838A1
(fr)
|
2005-08-03 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones utilisees pour le traitement de maladies respiratoires
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
BRPI0618179A2
(pt)
|
2005-11-01 |
2011-08-23 |
Targegen Inc |
inibidores de biaril meta pirimidina de cinases
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
KR20080083680A
(ko)
|
2005-12-23 |
2008-09-18 |
스미스클라인 비참 코포레이션 |
오로라 키나제의 아자인돌 억제제
|
EP1979350A1
(fr)
|
2006-01-17 |
2008-10-15 |
F.Hoffmann-La Roche Ag |
Derive aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine utile pour le traitement de la maladie d alzheimer via les recepteurs gaba
|
ZA200806871B
(en)
|
2006-02-14 |
2009-10-28 |
Vertex Pharma |
Dihydrodiazepines useful as inhibitors of protein kinases
|
TW200804389A
(en)
|
2006-02-14 |
2008-01-16 |
Vertex Pharma |
Dihydrodiazepines useful as inhibitors of protein kinases
|
US20070218135A1
(en)
|
2006-03-14 |
2007-09-20 |
Glenmark Pharmaceuticals Limited |
Sustained release matrix pharmaceutical composition
|
ATE477819T1
(de)
|
2006-05-03 |
2010-09-15 |
Novartis Ag |
Verwendung von organischen verbindungen
|
US20090312336A1
(en)
|
2006-05-19 |
2009-12-17 |
Astrazeneca Ab |
Dihydropteridine compounds as anti proliferative agents
|
WO2008009909A1
(fr)
|
2006-07-17 |
2008-01-24 |
Astrazeneca Ab |
Ptéridimones en tant que modulateurs de la kinase de type polo
|
ES2631003T3
(es)
|
2006-10-19 |
2017-08-25 |
Signal Pharmaceuticals, Llc |
Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
|
KR20090071668A
(ko)
|
2006-10-25 |
2009-07-01 |
크로마 데러퓨릭스 리미티드 |
암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체
|
WO2008066887A2
(fr)
|
2006-11-30 |
2008-06-05 |
Albert Einstein College Of Medicine Of Yeshiva University |
Inhibiteurs du gène bcl6 à petite molécule
|
MX367292B
(es)
|
2006-12-26 |
2019-08-13 |
Lantheus Medical Imaging Inc |
Ligandos para formacion de imagen de inervacion cardiaca.
|
JP2008156311A
(ja)
|
2006-12-26 |
2008-07-10 |
Institute Of Physical & Chemical Research |
Brd2ブロモドメイン結合剤
|
MX2009010034A
(es)
|
2007-03-22 |
2009-10-12 |
Hoffmann La Roche |
Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
|
WO2008137081A1
(fr)
|
2007-05-02 |
2008-11-13 |
The Trustees Of Columbia University In The City Of New York |
Composés de (5,6)-dihydronaphtalényle substitué en tant que contraceptifs masculins réversibles
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
NZ583061A
(en)
|
2007-08-15 |
2012-06-29 |
Vertex Pharma |
4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
|
NZ584760A
(en)
|
2007-09-25 |
2012-03-30 |
Takeda Pharmaceutical |
Polo-like kinase inhibitors
|
CN101878216B
(zh)
|
2007-09-28 |
2013-07-10 |
西克拉塞尔有限公司 |
作为蛋白激酶抑制剂的嘧啶衍生物
|
WO2009067547A1
(fr)
|
2007-11-19 |
2009-05-28 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinase de type polo
|
US20110028405A1
(en)
|
2007-12-20 |
2011-02-03 |
Richard John Harrison |
Sulfamides as zap-70 inhibitors
|
US8476260B2
(en)
|
2007-12-28 |
2013-07-02 |
Mitsubishi Tanabe Pharma Corporation |
Antitumor agent
|
CA2716079C
(fr)
|
2008-03-10 |
2018-01-16 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases
|
WO2009112490A1
(fr)
|
2008-03-11 |
2009-09-17 |
Cellzome Limited |
Sulfonamides en tant qu'inhibiteurs de zap-70
|
FR2928923B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
|
EP2112152A1
(fr)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones comme inhibiteurs Plk
|
JP2011527667A
(ja)
|
2008-06-18 |
2011-11-04 |
武田薬品工業株式会社 |
ハロ置換ピリミドジアゼピン
|
WO2010015340A1
(fr)
|
2008-08-06 |
2010-02-11 |
Bayer Schering Pharma Aktiengesellschaft |
Daa-pyridine comme ligand des récepteurs périphériques des benzodiazépines pour l'imagerie de diagnostic et le traitement pharmaceutique
|
WO2010032195A1
(fr)
|
2008-09-16 |
2010-03-25 |
Csir |
Imidazopyridines et imidazopyrimidines utilisés comme inhibiteurs de la transcriptase inverse du vih-1
|
BRPI0914406A2
(pt)
|
2008-10-30 |
2015-10-20 |
Circomed Llc |
composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero
|
PT2356123E
(pt)
|
2008-11-13 |
2012-10-31 |
Hoffmann La Roche |
Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
|
US9266890B2
(en)
|
2009-01-06 |
2016-02-23 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
CA2750106A1
(fr)
|
2009-01-23 |
2010-07-29 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la poly(adp-ribose)polymerase (parp)
|
CN102020643A
(zh)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
BR112012006652A2
(pt)
|
2009-09-25 |
2015-09-08 |
Vertex Pharma |
métodos para preparar os derivados de pirimidina úteis como inibidores de proteína cinase
|
GB0919431D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919426D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919434D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919423D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
PT2722334E
(pt)
|
2009-11-05 |
2016-03-11 |
Glaxosmithkline Llc |
Inibidor do bromodomínio da benzodiazepina
|
GB0919433D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
DK2496582T3
(en)
|
2009-11-05 |
2016-03-21 |
Glaxosmithkline Llc |
Benzodiazepine-BROMDOMAeNEINHIBITOR.
|
GB0919432D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Use
|
JP5841548B2
(ja)
|
2010-02-17 |
2016-01-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロプテリジノン、その製造方法及び使用
|
EP2571503B1
(fr)
|
2010-05-14 |
2015-01-07 |
Dana-Farber Cancer Institute, Inc. |
Compositions et leur utilisation dans le traitement des néoplasies, des maladies inflammatoires et d'autres affections
|
CN103119160B
(zh)
|
2010-05-14 |
2016-06-01 |
达那-法伯癌症研究所 |
用于调节代谢的组合物和方法
|
CA2799403C
(fr)
|
2010-05-14 |
2020-01-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions et methodes de traitement de la leucemie
|
JP6022442B2
(ja)
|
2010-05-14 |
2016-11-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
男性用避妊組成物および使用方法
|
ES2526671T3
(es)
|
2010-06-22 |
2015-01-14 |
Glaxosmithkline Llc |
Compuestos de benzotriazoldiazepina inhibidores de bromodominios
|
US20120014979A1
(en)
|
2010-07-16 |
2012-01-19 |
Alexander Dent |
Use of bcl6 inhibitors for treating autoimmune diseases
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
WO2012075456A1
(fr)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Inhibiteurs de bromodomaines et leurs utilisations
|
AU2012220620A1
(en)
|
2011-02-23 |
2013-10-03 |
Icahn School Of Medicine At Mount Sinai |
Inhibitors of bromodomains as modulators of gene expression
|
JP2014511389A
(ja)
|
2011-02-28 |
2014-05-15 |
エピザイム インコーポレイテッド |
置換6,5−縮合二環式ヘテロアリール化合物
|
CA2826674A1
(fr)
|
2011-03-07 |
2012-09-13 |
Fondazione Telethon |
Inhibiteurs de la phosphorylation de tfeb et leurs utilisations
|
GB201106799D0
(en)
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013033268A2
(fr)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Ligands bromodomaines bivalents et procédés d'utilisation de ceux-ci
|
WO2013033269A1
(fr)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant
|
DE102011082013A1
(de)
|
2011-09-01 |
2013-03-07 |
Bayer Pharma AG |
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
|
WO2013097052A1
(fr)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Inhibiteurs de bromodomaine
|
CN109529026A
(zh)
|
2012-02-17 |
2019-03-29 |
安迅生物制药公司 |
用于治疗流感和副流感患者的方法、化合物和组合物
|
WO2013148197A1
(fr)
|
2012-03-28 |
2013-10-03 |
The J. David Gladstone Institutes |
Compositions et procédés pour réactiver un virus d'immunodéficience latent
|
CA2878996C
(fr)
|
2012-08-08 |
2021-09-14 |
Novomatic Ag |
Procede et systeme de suivi d'activite de jeu
|
BR112015006537A2
(pt)
|
2012-09-28 |
2017-07-04 |
Oncoethix Sa |
dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
|
EP2917203B1
(fr)
|
2012-11-02 |
2019-04-03 |
Dana-Farber Cancer Institute, Inc. |
Procédé d'identification d'inhibiteurs de myc
|
US9609495B2
(en)
*
|
2012-11-16 |
2017-03-28 |
Verizon Patent And Licensing Inc. |
Central information management system
|
CN105229002A
(zh)
|
2012-12-20 |
2016-01-06 |
拜耳医药股份有限公司 |
抑制bet蛋白的二氢吡啶并吡嗪酮
|
US20140254659A1
(en)
|
2013-03-11 |
2014-09-11 |
Mediatek Inc. |
Video coding method using at least evaluated visual quality and related video coding apparatus
|
TW201444843A
(zh)
|
2013-03-11 |
2014-12-01 |
Abbvie Inc |
溴區結構域蛋白抑制劑
|
US10035800B2
(en)
|
2013-03-12 |
2018-07-31 |
Abbvie Inc. |
Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
CA2905070A1
(fr)
*
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methodes de traitement du cancer et de prevention d'une resistance a un medicament anticancereux
|
AU2014292888B2
(en)
|
2013-07-25 |
2018-03-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
AU2014323526B2
(en)
|
2013-09-19 |
2020-07-23 |
Dana-Farber Cancer Institute, Inc. |
Methods of BH3 profiling
|
WO2015081284A1
(fr)
|
2013-11-26 |
2015-06-04 |
Coferon, Inc. |
Ligands bromodomaines bivalents et procédés d'utilisation de ceux-ci
|
WO2015081280A1
(fr)
|
2013-11-26 |
2015-06-04 |
Coferon, Inc. |
Ligands de bromodomaine pouvant se dimériser dans une solution aqueuse
|
AU2014361381A1
(en)
*
|
2013-12-10 |
2016-06-16 |
Abbvie Inc. |
Bromodomain inhibitors
|
RU2673944C2
(ru)
|
2014-01-31 |
2018-12-03 |
Дана-Фарбер Кансер Институт, Инк. |
Дигидроптеридиноновые производные и их применения
|
EP3099693A4
(fr)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Utilisations des dérivés de diazépane
|
CA2936865A1
(fr)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Derives de diaminopyrimidine benzenesulfone et leurs utilisations
|
CA2936256A1
(fr)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Derives de diazepane et leurs utilisations
|
EP3110819A4
(fr)
|
2014-02-26 |
2017-08-02 |
Kyorin Pharmaceutical Co., Ltd. |
Composés hétérocycliques
|
SG11201607108XA
(en)
|
2014-02-28 |
2016-09-29 |
Tensha Therapeutics Inc |
Treatment of conditions associated with hyperinsulinaemia
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
CA2955074A1
(fr)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Derives de diazepane et leurs utilisations
|
CN106793775B
(zh)
|
2014-08-08 |
2020-06-02 |
达纳-法伯癌症研究所股份有限公司 |
二氢碟啶酮衍生物及其用途
|
JP2017537166A
(ja)
|
2014-12-05 |
2017-12-14 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
WO2016201370A1
(fr)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
|
WO2017007612A1
(fr)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
|
AU2016301195B2
(en)
|
2015-08-06 |
2022-09-01 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
|
EP3337476A4
(fr)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine
|
RU2746481C1
(ru)
|
2015-09-04 |
2021-04-14 |
Ф. Хоффманн-Ля Рош Аг |
Феноксиметильные производные
|
RS61803B1
(sr)
|
2015-09-09 |
2021-06-30 |
Jubilant Biosys Ltd |
Triciklični fuzioni piridin-2-on derivati i njihova upotreba kao inhibitora brd4
|
EA033978B1
(ru)
|
2015-09-11 |
2019-12-16 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
|
CN108472299A
(zh)
|
2015-09-11 |
2018-08-31 |
达纳-法伯癌症研究所股份有限公司 |
乙酰胺噻吩并***并二氮杂环庚三烯及其用途
|
KR20180049058A
(ko)
|
2015-09-11 |
2018-05-10 |
다나-파버 캔서 인스티튜트 인크. |
시아노 티에노트리아졸로디아제핀 및 그의 용도
|
BR112018010113B1
(pt)
|
2015-11-25 |
2022-06-14 |
Gilead Apollo, Llc |
Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc)
|
KR20180082557A
(ko)
|
2015-11-25 |
2018-07-18 |
길리어드 아폴로, 엘엘씨 |
트리아졸 acc 억제제 및 그의 용도
|
KR20180086191A
(ko)
|
2015-11-25 |
2018-07-30 |
길리어드 아폴로, 엘엘씨 |
2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물
|
EP4285923A3
(fr)
|
2015-11-25 |
2024-03-06 |
Visterra, Inc. |
Molécules d'anticorps se liant à april et leurs utilisations
|
ES2870037T3
(es)
|
2015-11-25 |
2021-10-26 |
Effector Therapeutics Inc |
Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
|
CA3004798C
(fr)
|
2015-11-25 |
2023-10-31 |
Gilead Apollo, Llc |
Inhibiteurs de l'acc a base d'esters et utilisations associees
|
SG11201803210YA
(en)
|
2015-11-25 |
2018-05-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
MX2018005222A
(es)
|
2015-12-01 |
2019-04-29 |
Nihon Nohyaku Co Ltd |
Compuesto de 3h-pirrolopiridina, n-óxido o sal del mismo, insecticida agrícola y hortícola que comprende el compuesto y método para usar los mismos.
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
EP3455219A4
(fr)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
|
WO2017201069A1
(fr)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
|
GB201608797D0
(en)
|
2016-05-19 |
2016-07-06 |
Ucb Biopharma Sprl |
Therapeutic use
|
WO2018064589A1
(fr)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante
|